GSK Promotes Ease Of Switching HIV Patients To Monthly Injection, Even During A Pandemic
Aiming To Seize Market Share From Gilead
Executive Summary
Doctors and patients need to be persuaded of the benefits of switching from familiar oral therapies to Cabenuva, the once-monthly anti-HIV injection.
You may also be interested in...
GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
ViiV Aims To Extend HIV Drug Durations With Halozyme’s Technology
ViiV Healthcare’s head of R&D tells Scrip that extending the durations of its long acting HIV treatments is possible using drug delivery technology from Halozyme Therapeutics to expand the body’s capacity to absorb injected medicines.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.